Cis-platinum (CDDP) plus etoposide (VP-16-213) and treatment of disseminated neuroblastoma.
Ten patients with neuroblastoma were treated with a standard pulsed administration schedule of cis-platinum and etoposide (VP16-213). Two patients are experiencing good partial responses lasting over 8 months. One other patient had a partial response. Toxicity was mild and limited to high frequency hearing loss, temporary increase in blood urea nitrogen, and myelosuppression. These data may be useful to compare with data from other more aggressive or different administration schedules of the drug combination.